PCSS is an investigational implant system that comprises non-segmental instrumentation with integrated screw fixation. Credit: Providence Medical Technology/PRNewswire.

Providence Medical Technology (PMT) has concluded patient enrolment in its study of the Posterior Cervical Stabilisation System (PCSS).

The prospective, multicentre, randomised, investigational device exemption FUSE Study is intended to assess the safety and effectiveness of PCSS in three-level cervical fusion patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

PMT has enrolled around 230 patients across 18 US spinal surgery sites to assess PCSS along with Anterior Cervical Discectomy and Fusion (ACDF) compared to ACDF alone in a superiority study.

The study, which commenced in May 2020, has been designed to evaluate Circumferential Cervical Fusion (CCF) in high-risk cervical fusion patients by generating level-one clinical evidence.

It involves patients who are at risk of failure following an ACDF fusion procedure due to various factors such as three-level disease, smoking, advanced age and diabetes.

It aims to explore the potential advantages of incorporating a tissue-sparing posterior cervical fusion alongside the ACDF procedure for these patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

When 100 patients have completed a two-year follow-up, the first comparative analysis of fusion and other clinical outcomes will be conducted.

PMT CEO and founder Jeff Smith said: “The completion of FUSE enrolment is an important milestone for high-risk spinal fusion patients.

“At Providence, we are on a mission to establish CCF as the standard of care for high-risk patients. We believe these patients require more and are hopeful the FUSE results will raise awareness of the extensive unmet need in the treatment of patients with risk factors for nonunion.”